A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth

SUPPLEMENTAL MATERIALS AND METHODS
Animal source, reagents, and tissue culture
Balb/c nude mice were purchased from Orient Bio Inc. (Gyeonggi, Korea). Non-obese diabetic/severe combined immunodeficient (NOD/LtSz-scid/IL2Rγ null ; referred to as NSG) mice were purchased from the Jackson Laboratory (Bar Harbor, ME) [1] . Newborn animals for transplantation experiments were obtained by inbreeding and were maintained under Specific-Pathogen-Free (SPF) conditions. Established and primary gastric cancer cells were cultured in RPMI containing 10% fetal calf serum (FCS) with antibiotics (R10) for routine maintenance unless otherwise mentioned. 293T cells were cultured in DMEM with 10% FCS and antibiotics (D10).
Expression constructs and shRNA-mediated knock down
Full length FGFR2IIIb (epithelial type transcript variant) was PCR-cloned into pcDNA3.1(+)/myc-His A (Invitrogen) using the indicated primer set (see Table  S2 ). Mutant FGFR2 with a deleted extracellular domain (E) from a.a. 22 to 377 (R2ΔE) or a deleted intracellular cytoplasmic domain (C) from a.a. 399 to 821 (R2ΔC) were generated by PCR deletion methods using specific primer sets (Table S2 ). MKN45 GC cells that express CD44 but not FGFR2, and hence display weak tumorigenicity in mice, were transfected with FGFR2-myc wild type (WT) by AMAXA program L-029 and were selected with G418 (neomycin; 400 μg/m). In KD experiments, at least two different small hairpin RNA (shRNA) sets selective for each FGFR2 (five sets), CD44 (two sets), and c-Myc (five sets) were used for cloning into constitutive or doxycycline (Dox)-inducible vectors (see Table S2 ). Three sets of c-Myc siRNA (sets 6, 7, 8) were employed wherever necessary. The plasmid was transfected into the cells with the AMAXA kit using solution V and protocol O17. Conditional sub-cell lines in which FGFR2 or CD44 is subjected to depletion by Dox treatment were generated by the standard antibiotic selection protocol.
Screening a highly tumorigenic GC cell line in the xenograft condition
Three BALB/c nude mice per cell line were subcutaneously (s.c.) injected with 10,000 cells from each of the eight human GC cell lines: SNU-1, SNU-5, SNU-16, SNU-484, SNU-620, SNU-638, SNU-719, MKN45.
Tumor size at 4 weeks post injection was measured. Where necessary, SNU-16 cells were stably labeled with firefly luciferase in order to monitor tumor growth and spreading real time in situ.
Confocal microscopy, immunofluorescence (IF) staining, and flow cytometry (FC)
Cells were smeared on the IF slide glass, dried quickly, fixed with 4% paraformaldehyde, permeabilized with 0.25 % Triton X-100 (where necessary), and incubated with 5 % (w/v) BSA in 1X PBS for 30 minutes at room temperature. The cells were then stained with diluted primary antibody (either dye non-conjugated or directly conjugated with FITC, PE, APC or PECy5), followed by incubation with the corresponding secondary antibody conjugated to Alexa Fluor ® 568 (red) or Alexa Fluor ® 488 (green) where necessary (see Table S1 for lists of antibodies). For confocal microscopy, the stained cells were mounted with Prolong Gold Antifade Reagent with DAPI (Invitrogen), and were examined using a Leica TCS SP5 spectral confocal system (LSM 710). For FC, cells in single cell suspension were incubated with the indicated dye conjugated or non-conjugated primary antibody. Where necessary, the indicated secondary antibody reactive to the non-conjugated primary antibody was used to label the cells. When necessary, the cell fractions positive for specific markers were then sorted by FACSAria (Beckton) and were subjected to secondary assays including tumor sphere, cell growth, real time quantitative PCR, or tumorigenesis.
Immunoprecipitation (IP) and western blotting
Cells were lysed in 1 ml of 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 50 mM Tris HCl pH 7.4 supplemented with 0.1% leupeptin and 0.01% phenylmethylsulfonyl fluoride (PMSF), and 200 nM sodium vanadate (NAV)/1 M sodium fluoride (NaF), where necessary. The lysates were cleared by centrifugation at 12,000 rpm for 5 min at 4°C and quantitated by Bradford method [2] . For IP, the lysate was precleared by protein A/G agarose and subjected to IP at 4°C overnight as previously described [3] . An equal amount of protein or equal volume of immune precipitate was separated on SDS-denaturing polyacrylamide gel, transferred to nylon membrane, and reacted to appropriate antibody.
Tumor sphere assay and patient-derived GC xenograft tumorigenic assay
To test xenograft tumorigenic assays of tumor samples from patient specimens, fresh GC tissues from 105 GC patients were minced and 0.2 cm 3 tissues were engrafted in nude mice (n ≥3 per each GC patient) for 12-16 weeks. Tumors were passaged in vivo to new mice from tumor-bearing mice without culturing in vitro until at least three passages were completed. Also, the indicated cell numbers of indicated cell lines were subcutaneously or orthotopically implanted in nude mice or NSG mice (wherever indicated) and tumor growth was determined by measuring diameters or luminescence (for the Luc-labeled cells). For in vitro cultures, tumor tissues were minced and cultured in flasks in RPMI 1640 supplemented with 10% FCS. For the tumor sphere assay, cells were plated at a density 100 cells per well in ultra low cluster 96 well plates (Costar, #3474) containing TeSR™ 2 media (STEMCELL, #05860), cultured for 14 days, and scored for size and number of spheres. low AGS GC cell line and subsequent activation by FGF7 drastically increased CD44 (see ascending dotted triangle) with concomitant decreases in FGFR2 because of receptor internalization. CD44 increased in FGFR2-transfected cells (red arrow) relative to pcDNA-transfected cells (red arrow). E. CD44 activation by hyaluronic acid (HA) results in an initial decrease and subsequent increase in CD44, which was colinear to p-FGFR2 and p-ERK, downstream of both CD44 and FGFR2 pathways [5] . HA treatment over 12 hr reduced CD44 levels (data not shown). 
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